NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.860
- +0.030+1.64%
Close Dec 20 16:00 ET
- 1.870
- +0.010+0.54%
Post 19:57 ET
92.64MMarket Cap-0.60P/E (TTM)
1.935High1.830Low839.44KVolume1.850Open1.830Pre Close1.56MTurnover2.81%Turnover RatioLossP/E (Static)49.81MShares20.22052wk High0.50P/B55.65MFloat Cap1.55052wk Low--Dividend TTM29.92MShs Float24.420Historical High--Div YieldTTM5.74%Amplitude1.550Historical Low1.861Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
HilleVax Stock Forum
📊⚡️📊
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
No comment yet